Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$44.03 USD
+0.84 (1.94%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $43.99 -0.04 (-0.09%) 4:18 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Dyne Therapeutics, Inc. (DYN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$45.50 | $56.00 | $37.00 | 5.35% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Dyne Therapeutics, Inc. comes to $45.50. The forecasts range from a low of $37.00 to a high of $56.00. The average price target represents an increase of 5.35% from the last closing price of $43.19.
Analyst Price Targets (10)
Broker Rating
Dyne Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, 10 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/DYN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/21/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
5/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/7/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
3/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/6/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
3/6/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
1/4/2024 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 10 |
Average Target Price | $45.50 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 154 of 252 |
Current Quarter EPS Est: | -0.72 |